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Abstract
Background: Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that
have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted
an open-label, single institution, phase Ib study to assess the safety and tolerability of using these two agents in
combination.
Methods: Study treatment consisted of ipilimumab given every 3 weeks, for a total of four infusions, concurrent
with peginterferon alfa-2b administered subcutaneous weekly for a total of 12 weeks. This was followed by
maintenance therapy with peginterferon alfa-2b administered subcutaneously weekly for up to 144 additional
weeks. The study was designed as a two-stage dose escalation scheme with continuous dose-limiting toxicity
monitoring during the induction phase.
Results: Thirty one patients received at least 1 dose of study treatment and 30 were assessable for efficacy
endpoints. We found that ipilimumab at 3 mg/kg dosing with peginterfeon alfa-2b at 2 μg/kg/week was the
maximum tolerated dose of this combination. The incidence of grade 3 drug-related adverse events (AEs) was 45.
2%. There were no grade 4/5 AEs. The overall response rate was 40% by immune-related response criteria. Median
progression-free survival was 5.9 months. The median overall survival was not reached with at a median follow-up
of 35.8 months.
Conclusions: We report that the combination of ipilimumab at 3 mg/kg dosing combined with peginterfeon alfa-
2b at 2 μg/kg/week demonstrated an acceptable toxicity profile and a promising efficacy signal. Further study of
this combination is warranted.
Trial registration: ClinicalTrials.gov identifier: NCT01496807, Registered December 19th, 2011.
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Background
Melanoma is amongst the most rapidly increasing cancers,
with over 76,000 new invasive cases predicted in the United
States in 2016 [1]. Over recent years, treatment for meta-
static melanoma has significantly evolved with the develop-
ment and regulatory approval of several therapeutic classes
of medications including both molecularly targeted and im-
munologically focused checkpoint inhibitor therapies.
Despite these recent advances, limitations remain in the
treatment of advanced melanoma. Treatment with molecu-
larly targeted therapies, while initially highly effective for
the majority of patients whose tumors harbor a BRAF
V600 mutation, typically lead to development of treatment
resistance [2–4]. While offering the potential for durable re-
sponses, treatment with checkpoint inhibitor immunother-
apies remain active in only a percentage of patients with
advanced melanoma, and most patients will require further
therapy [5–7]. Combination checkpoint inhibitor therapy is
associated with high rates of response but is also limited by
severe toxicity in more than half of treated patients [8].
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Interferon alfa has long been an adjuvant treatment
option for patients with high-risk resected melanoma
since its FDA approval in 1995. An important observa-
tion from adjuvant trials utilizing inferferon treatment is
that dose and duration of therapy may be an important
determinant of survival [9, 10]. Peginterferon alfa-2b was
developed to facilitate increased exposure to the inter-
feron alfa 2b molecule as compared to the nonpegylated
version. Adjuvant use of peginterferon alfa-2b was ap-
proved by the US FDA in 2011 for stage III melanoma
after showing an improvement in relapse-free survival
compared to observation a in phase III study [11].
Ipilimumab, a monoclonal antibody directed against
the cytotoxic T-lymphocyte antigen 4 (CTLA-4), was the
first checkpoint inhibitor approved for use in melanoma
after showing efficacy in two phase III trials [12, 13].
Though treatment with antibodies directed against the
programmed death 1 (PD-1) protein have largely sup-
planted ipilimumab as first line therapy for advanced
melanoma, ipilimumab continues to have an important
therapeutic role either as part of combination check-
point inhibitor therapy or as a second line immunother-
apy option for those patients with progression after PD-
1 inhibitor therapy.
Given the need for improved efficacy of available sys-
temic therapies for advanced melanoma, we conducted a
phase IB study of the combination of ipilimumab and
peginterferon alfa-2b in patients with unresectable mel-
anoma. These agents were selected based on the proven
efficacy of either of these two agents alone as well as the
non-overlapping mechanism of action. Interferon alfa
treatment has been shown to induce an inflammatory
tumor microenvironment, with upregulation of major
histocompatibility complex antigen processing and co-
stimulatory molecules and induction of T helper type 1
(Th1) polarization [14–19]. The antitumor impact of
interferon, however, may be suppressed by tumor im-
mune tolerance mechanisms, leading to limited clinical
activity of interferon as a single agent. CTLA-4 is a key
regulator of immune tolerance and a negative regulator
of T cell activation [20, 21]. We therefore hypothesized
that CTLA-4 inhibition might alter the balance of tumor
tolerogenic mechanisms and potentiate the clinical activ-
ity of the interferon-induced inflammatory microenvir-
onment. In addition to the immunologic rationale of this
combination, we were motivated by the encouraging re-
sults of a phase II study of treatment with high-dose
interferon alfa-2b plus the anti-CTLA-4 antibody treme-
limumab showed acceptable toxicity and a response rate
of over 30% [22]. We hypothesized that the addition to
peginterferon alfa-2b to ipilimumab treatment might en-
hance the efficacy of CTLA-4 blockade. The primary ob-
jective of the study was to assess the safety and
tolerability of this combination. The secondary
objectives were to determine response rates by immune-
related response criteria (irRC), progression free survival,
and overall survival. In patients treated with either inter-
feron alfa-2b or ipilimumab, retrospective analyses have
suggested that there is an association of autoimmune
phenomena with clinical benefit [23–26]. Therefore an
additional planned exploratory endpoint was to assess
the rate of autoimmune antibody induction and whether
this was associated with anti-tumor response with the
combination.
Methods
This was a phase Ib, open-label study conducted at the
H. Lee Moffitt Cancer Center (NCT01496807) under an
IND exemption grated by the FDA. The main inclusion
criteria were: patients age ≥16 years with a histological
and/or cytological confirmed diagnosis of unresectable
stage IIIB/C-IV melanoma untreated systemically other
than a BRAF inhibitor for metastatic disease; adequate
renal, hepatic, and hematologic parameters; and ECOG
performance status of 0 or 1. Patients with a history of
severe cardiac comorbidities, uncontrolled diabetes or
thyroid dysfunction, history of HIV seropositivity, pa-
tients suffering from active autoimmune disease other
than controlled hypothyroidism or vitiligo, pre-existing
severe psychiatric conditions, patients on systemic cor-
ticosteroid therapy for any reason, and patients with un-
controlled brain metastases were excluded. The study
was approved by the institutional review board at the H.
Lee Moffitt Cancer Center in Tampa, FL. All patients
provided written informed consent.
Study treatment consisted of ipilimumab given every 3
weeks, for a total of four infusions, concurrent with
peginterferon alfa-2b administered subcutaneous weekly
for a total of 12 weeks. This was followed by mainten-
ance therapy with peginterferon alfa-2b only, adminis-
tered subcutaneously weekly for up to 144 additional
weeks. The study was designed with a two-stage dose es-
calation scheme with continuous dose-limiting toxicity
(DLT) monitoring during the induction phase of the first
dose level (DL) and a total enrollment of 36 planned to
observe 30 evaluable patients. The first cohort of up to
15 patients would be given ipilimumab at a 3 mg/kg
dose and peginterferon alfa-2b at 3 μg/kg/week. Dose es-
calation to DL 2 (ipilimumab at 10 mg/kg) would follow
if all 15 patients in DL 1 had initiated treatment, and
fewer than 3 of 10 patients have had a DLT after com-
pleting 12 weeks of treatment. If the number of DLTs
during the ipilimumab induction period in either cohort
exceeded ≥2 in first 6 patients, ≥3 of the first 10 patients,
or ≥5 of the first 15 patients, and the DLT was not felt
to be an immune-related adverse event (irAE) caused by
ipilimumab, then patients thereafter would be treated at
DL -1 with ipilimumab 3 mg/kg week and peginterferon
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2 μg/kg/week until a total of 30 patients would be
treated. At the reduced dose of peginterferon (DL -1),
again continuous DLT monitoring was performed during
the induction phase and a second dose reduction in
peginterferon (DL -2) could be undertaken if excessive
peginterferon alfa-2b related DLTs were observed. The
dose escalation plan of the study is summarized in
Table 1.
Dose modification guidelines for peginterferon alfa-2b
were pre-specified and similar to the package insert for
this drug. Similar to the EORTC 18991 study, the intent
of the protocol was for the investigator to modify the
dose of peginterferon alfa-2b as needed in order to keep
the patient on treatment while maintaining a ECOG per-
formance status of 0 or 1. Dose reduction of ipilimumab
was not allowed. Guidelines for ipilimumab dose skip-
ping, discontinuation, and management of ipililimumab-
related irAEs were prespecified and similar to the pack-
age insert.
Safety assessments were performed at during induction
therapy and every 3 months during the maintenance
phase of the trial by history and physical examination,
ECOG performance status evaluation, and regular moni-
toring of hematology, blood chemistry, and urinalysis.
Thyroid function was monitored on screening and at week
12 and months 6, 12, 15, 18, 21, 24, 27, 30, 33, and 36.
Additionally, presence of vitiligo as an autoimmune event
was assessed with a Wood’s Lamp at each clinic visit. Be-
ginning at the week 12 visit, disease status was monitored
by physical examination and imaging studies every
12 weeks during years 1–3 until disease progression or the
treatment regimen was concluded. For patients who came
off treatment for toxicity, they were monitored for PFS
with CT scans every 3 months up to year 3, then every
6 months thereafter indefinitely. Brain MRI for disease
monitoring was completed at every other imaging evalu-
ation. Once a patient progressed, they were followed for
OS every 3 months indefinitely.
Blood samples for autoimmune antibody assessments
were collected pre-treatment immediately prior to the first
dose and at week 6, 12 and then every 3 months up to
month 36. Samples were taken immediately prior to ipili-
mumab and/or peginterferon alfa-2b administration and
were tested by enzyme-linked immunosorbent assays
(Quanta lie, Inova Diagnostics) for antinuclear antibodies,
anti-DNA antibodies, antithyroglobulin antibodies,
antimicrosomal antibodies, and anticardiolipin antibodies.
Samples from month 15 on were stored and would only
be assessed if equivocal data arise from the samples taken
during the first 12 months of therapy.
Results
Between February 17th 2012 and December 5th 2013,
33 patients were screened and 31 patients were enrolled
on treatment. The median patient age was 65 [range 38–
83]. There were 24 cutaneous primaries, 5 unknown pri-
maries and 2 acral melanomas. All patients had stage IV
disease at the time of trial enrollment. Most patients
were systemic therapy naïve. Approximately 80% of pa-
tients had a normal baseline serum lactate dehydrogen-
ase (LDH) level. A significant majority of patients had
tumors that were BRAF V600 wild type. Additional
baseline characteristics of the treatment population are
detailed in Table 2.
Seven patients were treated at Dose Level (DL) 1, and
the remaining 24 at DL-1. Overall, 27 patients (87%)
completed the 3 month induction phase of treatment.
Three patients discontinued prior to this first planned
restaging due to early disease progression, and 1 was
taken off study prior to completing 1 cycle due to a
change in diagnosis. Ten additional patients had pro-
gression of disease at the time of first restaging and so
did not proceed with the maintenance phase of the trial.
Of the 17 remaining patients that completed the induc-
tion phase of treatment without disease progression,
only 1 completed the full 3 years of treatment, including
the 144 additional weeks of maintenance peginterferon
alfa-2b. Eight patients discontinued maintenance treat-
ment due to later disease progression and the remaining
8 due to toxicity and/or patient preference.
Dose limiting toxicity and maximum tolerated dose
The first seven patients initiated treatment on DL1, and 3
patients experienced G3 gastrointestinal symptoms (nausea,
vomiting and/or abdominal pain), which was considered to
be a DLT related to peginterferon alfa-2b. As per pre-
specified criteria, subsequent patients were treated at DL
-1, with peginterferon alfa-2b reduced from 3 μg/kg/week
to 2 μg/kg/week. At DL -1, pre-specified DLT limits were
not reached in the first 15 patients treated at this dose, es-
tablishing this dosing schedule as the maximum tolerated
dose (MTD) and allowing for further cohort expansion at
this dose level to complete enrollment.
Safety
The safety population was comprised of all 31 patients
receiving at least 1 dose of study drug. All patients expe-
rienced grade 1 toxicity, 28 patients (90.3%) experienced
at least grade 2 toxicity, and 14 patients (45.2%) experi-
enced a grade 3 toxicity felt by investigators to be
Table 1 Dose escalation study design
Dose Level Peginterferon alfa-2b Ipilimumab
−2 1 μg/kg/week 3 mg/kg
−1 2 μg/kg/week 3 mg/kg
1 3 μg/kg/week 3 mg/kg
2 3 μg/kg/week 10 mg/kg
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attributable to treatment (Table 3). Eight patients
(25.8%) experienced a grade 3 immune related adverse
event felt related to ipilimumab treatment including rash
(4), colitis (2) and endocrinopathies (2). All were man-
aged with steroids with resolution or hormone replace-
ment, as appropriate. Ten patients (32.2%) experienced a
grade 3 toxicity related to peginterferon alfa-2b therapy,
most commonly hematologic (4) and gastrointestinal (3).
All peginterferon alfa-2b related toxicities resolved with
supportive care and treatment interruption/discontinu-
ation. Neither any grade 4 toxicities nor treatment-
related deaths occurred.
Efficacy
Thirty patients were evaluable for efficacy. One add-
itional patient experienced rapid disease progression
shortly after initiation of therapy and underwent surgery
for spinal cord compression. Pathological evaluation of
this specimen revealed that the patient was affected by a
high-grade carcinoma, rather than a melanoma as was
believed based on previous biopsy. This patient was
taken off further study treatment and was not consid-
ered evaluable for efficacy endpoints.
Of 30 evaluable patients, 12 (40%) experienced a con-
firmed response (1 CR, 11 PR) by irRC. Three additional
patients had stable disease of at least 24 weeks (SD), for
a disease control rate (CR+PR+SD) of 50% (Fig. 1).
There was no statistical difference in the efficacy rates
between DL1 and DL-1, though the study was not pow-
ered to detect a difference. The median progression free
survival was 5.9 months (Fig. 2a). Five patients (16.7%)
remain alive and progression free without further treat-
ment with a median follow-up of 40.3 months (range
33.0–46.4 months). The median overall survival was not
reached in this study, with 18 patients (60%) alive at the
time of censoring with a median follow-up of
35.8 months (range 19.7–50.2 months) (Fig. 2b).
Autoimmunity as a biomarker of treatment response
Seven patients were diagnosed with autoimmune vitiligo
during the study period. Notably, 6 of these patients
(85.6%) experienced an objective response, and the
remaining patient experienced stable disease of >1 year.
The correlation between vitiligo and objective response
was highly statistically significant (p = 0.009). The me-
dian time from start of treatment to development of viti-
ligo was 224 days (range 140–374). In an attempt to
mitigate lead-time bias of the association of vitiligo with
positive clinical outcome, we performed landmark ana-
lysis of overall survival between those with and without
vitiligo at 6, 9, and 12 month time points. Overall sur-
vival of patients presenting with vitiligo was not signifi-
cantly improved compared with patients alive but free of
vitiligo at these time points (p = 0.94, p = 0.46, p = 0.69,
respectively).
Four of the patients had a positive screening result for
an autoimmune antibody at the time of study entry.
Twelve patients developed a positive result during treat-
ment for one or more antibodies of a previously negative
screen, including antithyroglobulin (7), anti-DNA (5),
anticardiolipin IgM (2), anticardiolipin IgG (2) and anti-
nuclear (1). There was no significant association between
development of a new positive autoantibody and object-
ive disease response (33.3% with a new autoantibody
positive vs. 44.4% without, p = 0.71).
Discussion
We report the final results of clinical trial NCT01496807,
an open label, phase IB study of ipilimumab with peginter-
feron alfa-2b in patients with unresectable stage IV melan-
oma. We found that ipilimumab at 3 mg/kg plus
peginterferon alfa-2b at 2 μg/kg weekly was the maximal
Table 2 Baseline characteristics of the treatment population
(n = 31) at the time of study enrollment
Baseline Characterisitcs of Treatment Population (n = 31)















LDH level, n (%)
Normal 25 (80.6%)
Elevated 6 (19.4%)
BRAF V600, n (%)
wild type 26 (83.9%)
V600E 3 (9.7%)
V600K 2 (6.5%)
Prior systemic therapy, n (%)
None 28 (90.3%)
BRAF targeted therapy 1 (3.2%)
cytotoxic chemotherapy 1 (3.2%)
adjuvant vaccine clinical trial 1 (3.2%)
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Table 3 Drug related adverse events in the safety population (n = 31), including any AE experienced by ≥5% of the cohort and all
grade 3 AEs. Note that there were no grade 4 or 5 drug related AEs
Toxicity category Description Grade 1–2 Percent Grade 3 Percent
Blood and lymphatic system disorders Anemia 5 16.1% - -
Cardiac disorders Atrial fibrillation - - 1 3.2%
Endocrine disorders Hypophysitis 1 3.2% 1 3.2%
Hypothyroidism 2 6.5% 1 3.2%
Eye disorders Dry Eye 3 9.7% - -
Gastrointestinal disorders Abdominal Pain 2 6.5% - -
Colitis 2 6.5% 2 6.5%
Constipation 4 12.9% - -
Diarrhea 17 54.8% - -
Dry Mouth 5 16.1% - -
Flatulence 2 6.5% - -
Nausea 16 51.6% 2 6.5%
Vomiting 8 25.8% 1 3.2%
General disorders and administration site conditions Chills 19 61.3% - -
Fatigue 28 90.3% 1 3.2%
Fever 15 48.4% - -
Flu like symptoms 7 22.6% - -
Injection site reaction 7 22.6% - -
Infusion reaction 3 9.7% - -
Malaise 3 9.7% - -
Night Sweats 4 12.9% - -
Investigations Alanine aminotransferase increased 8 25.8% - -
Alkaline phosphatase increased 2 6.5% - -
Aspartate aminotransferase increased 8 25.8% - -
Lymphocyte count decreased 4 12.9% 1 3.2%
Neutrophil count decreased 3 9.7% 3 9.7%
Platelet count decreased 6 19.4% - -
Weight loss 5 16.1% - -
White blood cell decreased 8 25.8% 2 6.5%
Metabolism and nutrition disorders Anorexia 16 51.6% - -
Dehydration 1 3.2% 2 6.5%
Hyponatremia - - 2 6.5%
Muskuloskeletal and connective tissue disorders Arthralgia 15 48.4% 1 3.2%
Myalgia 2 6.5% - -
Nervous system disorders Dizziness 5 16.1% - -
Dysgeusia 8 25.8% - -
Headache 17 54.8% - -
Syncope - - 1 3.2%
Psychiatric disorders Anxiety 3 9.7% - -
Depression 5 16.1% - -
Respiratory, thoracic and mediastinal disorders Cough 7 22.6% - -
Dyspnea 8 25.8% - -
Productive Cough 2 6.5% - -
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tolerated dose of this combination. Though not the primary
endpoint of this study, we noted a promising efficacy signal
with 40% of patients experiencing an objective response,
17% of patients having prolonged progression free survival
without further therapy, and the majority of patients
remaining alive with approximately 3 years of follow-up
data. We also note that the development of vitiligo as an
autoimmune toxicity was highly associated with disease re-
sponse, consistent with previous reports [27, 28]. Survival
of patients developing vitiligo was not significantly im-
proved versus to those who did not experience this toxicity
when compared using landmark analysis to mitigate lead-
time bias. These comparisons, however, were limited by
small patient numbers.
The significant toxicities observed on this study were
well within the range of those expected based on the in-
dividual toxicity profiles of the two agents used. In the
EORTC 18991 study, peginterferon alfa-2b use was asso-
ciated with a 57% rate of G3 toxicity at the 3 μg/kg/week
dose [29]. We found this dose combined with ipilimu-
mab at 3 mg/kg to have an unacceptably high rate of G3
toxicity, requiring hospitalizations in 3 of the first 7
patients treated. Within the context of combination
therapy this rate of early hospitalizations due to pegin-
terferon could potentially compromise the ability to re-
ceive adequate checkpoint inhibition. The type of
ipilimumab-related immune related adverse events was
also very similar to previous reports, with rash, colitis
and endocrinopathies being observed. It should be
noted, however, that the rate of G3 ipilimumab-related
toxicities, and in particular G3 rash (13%), was higher
than in most previous reports of single agent ipilimumab
use at this dose [25]. Though it is possible that
ipilimumab-related immune toxicities were potentiated
by the addition of peginterferon, we speculate that the
enhanced efficacy observed with this combination, lead-
ing to greater numbers of patients surviving long enough
to experience delayed toxicities, may also contribute.
The efficacy observed in this trial appears superior to
previous reports of single agent ipilimumab use [13, 30].
Though this study was not designed for assessment of
efficacy endpoints, the response rate observed is promis-
ing when considering ipilimumab monotherapy response
rates in prior trials. One previous phase II study of
Table 3 Drug related adverse events in the safety population (n = 31), including any AE experienced by ≥5% of the cohort and all
grade 3 AEs. Note that there were no grade 4 or 5 drug related AEs (Continued)
Skin and subcutaneous tissue disorders Alopecia 6 19.4% - -
Dry Skin 4 12.9% - -
Pruritus 18 58.1% 2 6.5%
Rash 22 71.0% 4 12.9%
Skin hypopigmentation 7 22.6% - -
Any 31 100% 15 48.4%
Fig. 1 Waterfall plot depicting best response as a percentage change from baseline of target lesions. irRC cutoffs for partial response and
progressive disease are shown (dotted lines)
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treatment with interferon alfa plus anti-CTLA-4 also
noted encouraging efficacy [22]. Differences in baseline
characteristics and response criteria between studies
limit direct comparison of these two studies. Notably,
patients in our study were predominantly treatment
naïve and with normal baseline LDH levels, both of
which may be associated with more favorable outcome.
Despite differences in study design and agents used, the
favorable efficacy signal in both studies collectively sup-
ports the idea of future investigation of similar combin-
ation therapy approaches. We caution, however, that our
study results need to be viewed in context of recent ad-
vances in the treatment of advanced melanoma. Specific-
ally, this trial was conducted prior to availability of PD-1
inhibitor therapy, and all patients on trial were check-
point inhibitor therapy naïve. As ipilimumab monother-
apy is now more commonly given in the setting of PD-1
inhibitor failure, future study of interferon alfa combined
with checkpoint inhibition will likely focus on PD-1 in-
hibitor combinations, for which studies are already
ongoing, or in the second line setting with ipilimumab
after failure of PD-1 inhibitor based therapy. Our study
also does not address the optimal duration of peginter-
feron alfa-2b maintenance therapy, or whether a main-
tenance phase is even beneficial. Of note, only a single
patient in this study completed the planned 3 year
peginterferon maintenance.
Conclusions
Despite recent advances in the treatment of advanced
melanoma, there is a need for continued improvement
in treatment options. We report that the combination of
ipilimumab at 3 mg/kg dosing combined with peginter-
feon alfa-2b at 2 μg/kg/week demonstrated an acceptable
toxicity profile and a promising efficacy signal. Further
study of this combination is warranted. More generally,
this trial adds to the growing rationale that novel combi-
nations of immunotherapeutic agents should be investi-
gated in advanced melanoma.
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